LKT Laboratories, Inc.

AZD-8055

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID A9914
CAS No. 1009298-09-2
Chemical Name

Synonym AZD-8055

Formula $C_{25}H_{31}N_5O_4$
Formula Wt. 465.55
Melting Point
Purity ≥98%
Solubility DMSO 50 mg/mL warmed (107.4 mM)
Ethanol 3 mg/mL (6.44 mM)
Water Insoluble
Store Temp -20°C
Ship Temp Ambient



Bulk quanitites available upon request

Product ID	Size
A9914	5 mg
A9914	25 mg
A9914	50 mg

Description AZD-8055 is an ATP-competitive mTORC1/2 inhibitor that exhibits immunosuppressive and anticancer chemotherapeutic activities. AZD-8055 promotes antibody class switching in B cells at low doses and decreases B cell proliferation and differentiation at high doses. In vivo, this compound suppresses CC4+ and CD8+ T cell proliferation, increasing survival among MHC-mismatched heart transplant recipients. In vitro, AZD-8055 decreases viability of brain tumor cells; in vivo, it inhibits tumor growth.

References

Limon JJ, So L, Jellbauer S, et al. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5076-85. PMID: 25385646.

Luchman HA, Stechishin OD, Nguyen SA, et al. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res. 2014 Nov 15;20 (22):5756-67. PMID: 25316808.

Rosborough BR, Raïch-Regué D, Liu Q, et al. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant. 2014 Sep;14(9):2173-80. PMID: 25307040.